StockNYSE · US · USDHealthcare · Medical Instruments & Supplies
$TFX
TELEFLEX INC
Teleflex is a global medical technology company that designs, develops, manufactures and supplies primarily single-use devices for hospitals and healthcare providers. It sells products worldwide through its direct sales force, independent representatives and distributor networks. Its three reportable segments are Americas, EMEA, covering Europe, the Middle East and Africa, and Asia, covering Asia Pacific. Product categories include vascular and emergency medicine, interventional and surgical devices. Brands and products include Arrow catheters, EZ-IO access systems, QuikClot hemostatic products, GuideLiner and Turnpike catheters, the MANTA vascular closure device, and surgical products under brands such as Weck, MiniLap and Pilling. Teleflex also has Acute Care, Interventional Urology and OEM businesses. OEM designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company sells its products to hospitals, healthcare providers and distributors. Its major manufacturing operations are in the Czech Republic, Malaysia, Mexico and the United States. Teleflex is headquartered in Wayne, Pennsylvania.
Teleflex (TFX) reported Q3 revenue of $567.8M, up 0.2% GAAP and 3.0% constant-currency. Adjusted EPS rose 39.2% to $2.63, beating estimates. The company raised 2026 adjusted EPS guidance to $7.50-$7.75. Margins expanded, debt decreased, and share repurchases totaled $350M. Growth was driven by vascular and surgical businesses, while interventional revenue saw modest improvement. Integration challenges and tariff exposure remain.
Teleflex has opened a new machining shop in Chihuahua, investing US$5 million to expand high-precision medical device production. The 750 sqm facility adds to the company's four existing plants in the state, employing 2,000 people. Index Chihuahua praised the investment for boosting industrial competitiveness and medical device supply chains. Teleflex is a US-based multinational specializing in medical technologies.
Truist Securities kept Teleflex at Hold but raised its price target to $167 from $142, a 17.6% increase. This implies a 10.7% upside from the Nov 6 close of $150.87. Recent analyst price targets for Teleflex range from $142 to $175.
via TradingView
TFX sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TFX (TELEFLEX INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TFX coverage spans earnings and financial news.
What's driving TFX
No new material information; the article recaps previously released earnings and guidance.
Teleflex has opened a new machining shop in Chihuahua, investing US$5 million to expand high-precision medical device production. The 750 sqm facility adds to the company's four existing plants in the state, employing 2,000 people. Index Chihuahua praised the investment for boosting industrial competitiveness and medical device supply chains. Teleflex is a US-based multinational specializing in medical technologies.
AlphAI scores every news story that mentions TFX with an AI model for sentiment and relevance, and aggregates insider trades from TELEFLEX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Teleflex (TFX) reported Q3 revenue of $567.8M, up 0.2% GAAP and 3.0% constant-currency. Adjusted EPS rose 39.2% to $2.63, beating estimates. The company raised 2026 adjusted EPS guidance to $7.50-$7.75. Margins expanded, debt decreased, and share repurchases totaled $350M. Growth was driven by vascular and surgical businesses, while interventional revenue saw modest improvement. Integration challenges and tariff exposure remain.
Teleflex has opened a new machining shop in Chihuahua, investing US$5 million to expand high-precision medical device production. The 750 sqm facility adds to the company's four existing plants in the state, employing 2,000 people. Index Chihuahua praised the investment for boosting industrial competitiveness and medical device supply chains. Teleflex is a US-based multinational specializing in medical technologies.
Truist Securities kept Teleflex at Hold but raised its price target to $167 from $142, a 17.6% increase. This implies a 10.7% upside from the Nov 6 close of $150.87. Recent analyst price targets for Teleflex range from $142 to $175.
Teleflex (NYSE: TFX) reported Q3 earnings, highlighting progress in integrating Vascular Intervention, with revenue up 0.2% to $210.3M. Vascular and Surgical revenues grew 4.6% and 5.1% respectively. Adjusted gross margin increased to 66.8%, including a $16.5M tariff refund. The company expects 2026 adjusted operating margin of 20% and remains optimistic about earnings potential. Teleflex repurchased $350M in stock and paid off a $700M term loan.
Teleflex (TFX) raised its Q3 2026 earnings guidance, continued share buybacks, and affirmed its quarterly dividend. The stock has risen 21.20% in 30 days and 23.26% year-to-date, but remains down over longer periods. Analysts debate its valuation, with some seeing it as 2% undervalued at $150.87, while others note a high P/E of 68.3x.
RBC Capital reaffirmed its Outperform rating for Teleflex and increased its price target to $175 from $155, suggesting a 15% upside from the Nov 5 close of $152.15.
Wells Fargo reaffirmed Teleflex's Equal-Weight rating and increased its price target to $167 from $138, indicating a 9.8% upside from the last close of $152.15, according to the bank.
Mizuho raised its price target for Teleflex (NYSE:TFX) to $160, citing margin gains and steady sales. The stock is up 26% YTD. Teleflex reported Q3 2026 revenue growth of 3.0% and raised its 2026 EPS guidance to $7.50-$7.75. The company also completed $350M in share buybacks.
Teleflex Incorporated reported Q3 2026 earnings, highlighting a strategic shift to a Global Business Unit structure and positive growth in the Interventional segment. The company expects 2027 to show improved earnings and margins due to share buybacks, debt reduction, and new product innovations. A $16.5 million tariff refund boosted margins, and the company plans $1 billion in share repurchases and $800 million in debt reduction.
Teleflex reported Q3 2026 revenue of $567.8M, matching estimates, and adjusted EPS of $2.63, beating estimates by 39.1%. The company raised its full-year adjusted EPS guidance to $7.63. Operating margin improved to 18.6% from -73.3% year-over-year.